medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2013, Número 03-04

<< Anterior Siguiente >>

Medicina & Laboratorio 2013; 19 (03-04)


Escherichia coli resistente a la fosfomicina: un hecho que nos invita a reflexionar sobre la resistencia bacteriana

López VJA, Campuzano MG

Idioma: Español
Referencias bibliográficas: 32
Paginas: 183-188
Archivo PDF: 341.72 Kb.


RESUMEN

la resistencia bacteriana es un problema de salud pública que dificulta cada vez más el tratamiento de los pacientes con infecciones del tracto urinario o de otros sistemas. Si bien los casos de resistencia estaban restringidos al entorno hospitalario, en la actualidad son más comunes las infecciones adquiridas en la comunidad causadas por bacterias multirresistentes. En este artículo se presenta una reflexión acerca del riesgo que representa la multirresistencia, y el surgimiento de resistencia a las alternativas terapéuticas para el tratamiento exitoso de las infecciones de tracto urinario, así como se reflexiona sobre puntos clave relacionados con el uso adecuado de las pruebas diagnósticas y los antibióticos en este tipo de infecciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis 2012; 25: 371-377.

  2. Amábile-Cuevas CF. Global perspectives of antibiotic resistance In: J. SA, Byarugaba DK, Amábile-Cuevas CF, Hsueh P, Kariuki S, Okeke IN, eds. Antimicrobial Resistance in Developing Countries. New York: Springer; 2010.

  3. Pitout JD. Enterobacteriaceae that produce extended- spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg? Curr Pharm Des 2013; 19: 257-263.

  4. Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol 2011; 156: 131-136.

  5. McCarter YS, Burd EM, Hall GS, Zervos M. Laboratory Diagnosis of Urinary Tract Infections. Coordinating ed., S. E. Sharp. ASM Press, Washington, DC. 2009; Cumitech 2C, .

  6. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002; 113 Suppl 1A: 14S-19S.

  7. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The Pensieres Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control 2012; 1: 11.

  8. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Maya G. López-Vargas JA, Campuzano-Maya G Diseases. Clin Infect Dis 2011; 52: e103-120.

  9. Bours PH, Polak R, Hoepelman AI, Delgado E, Jarquin A, Matute AJ. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis 2010; 14: e770-774.

  10. Leal AL, Cortes JA, Arias G, Ovalle MV, Saavedra SY, Buitrago G, et al. Emergencia de fenotipos resistentes a cefalosporinas de tercera generacion en Enterobacteriaceae causantes de infeccion del tracto urinario de inicio comunitario en hospitales de Colombia. Enferm Infecc Microbiol Clin 2012.

  11. Grupo de Estudio de Resistencia de Medellín (GERMEN). http://www.grupogermen.org/pdf/escherichia. pdf Consultado en abril de 2013

  12. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 4006-4008.

  13. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc 2011; 86: 480-488.

  14. Carlet J, Mainardi JL. Antibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin? Clin Microbiol Infect 2012; 18: 1-3.

  15. Gobernado M. Fosfomicina. Rev Esp Quimioterap 2003; 16: 15-40.

  16. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.

  17. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.

  18. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-1877.

  19. Palou J, Angulo JC, Ramon de Fata F, Garcia-Tello A, Gonzalez-Enguita C, Boada A, et al. Randomized Comparative Study for the Assessment of a New Therapeutic Schedule of Fosfomycin Trometamol in Postmenopausal Women with Uncomplicated Lower Urinary Tract Infection. Actas Urol Esp 2013; 37: 147- 155.

  20. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended- spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459-2463.

  21. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010; 54: 3061-3064.

  22. He L, Partridge SR, Yang X, Hou J, Deng Y, Yao Q, et al. Complete nucleotide sequence of pHN7A8, an F33:A-:B-type epidemic plasmid carrying blaCTX- M-65, fosA3 and rmtB from China. J Antimicrob Chemother 2013; 68: 46-50.

  23. Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012; 67: 2843-2847.

  24. Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamaseproducing Escherichia coli urinary isolates( 2005-2009-2011)]. Rev Esp Quimioter 2013; 26: 43-46.

  25. Wilson DT, May DB. Potential Role of Fosfomycin in the Treatment of Community-Acquired Lower Urinary Tract Infections Caused by Extended-Spectrum beta-Lactamase-Producing Escherichia coli. Am J Ther 2011.

  26. Medina-Bombardo D, Jover-Palmer A. Does clinical examination aid in the diagnosis of urinary tract infections in women? A systematic review and meta- analysis. BMC Fam Pract 2011; 12: 111.

  27. Mishra B, Srivastava S, Singh K, Pandey A, Agarwal J. Symptom-based diagnosis of urinary tract infection in women: are we over-prescribing antibiotics? Int J Clin Pract 2012; 66: 493-498.

  28. Raz R. Asymptomatic bacteriuria. Clinical significance and management. Int J Antimicrob Agents 2003; 22 Suppl 2: 45-47.

  29. Johnson JD, O’Mara HM, Durtschi HF, Kopjar B. Do urine cultures for urinary tract infections decrease follow-up visits? J Am Board Fam Med 2011; 24: 647- 655.

  30. File TM, Jr., Solomkin JS, Cosgrove SE. Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. Clin Infect Dis 2011; 53 Suppl 1: S15-22.

  31. Duchene E, Montassier E, Boutoille D, Caillon J, Potel G, Batard E. Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection 2013; 41: 211-214.

  32. McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, Macgowan A, et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother 2011; 66: 1396- 1404.




2020     |     www.medigraphic.com